Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release: Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types

04/07/2021 | 01:00am EDT
 
   -- Anti-p53 antibodies are antibodies that mistakenly target a patient's own 
      tissues, leading to a growth of solid tumors. 
 
   -- Screening for Anti-p53 helps to diagnose throat, bowel and breast cancers 
      earlier, thereby increasing the chances that a patient responds to a 
      treatment 
 
   -- The Elecsys Anti-p53 could be used to monitor cancer cell remnants in the 
      patient's body 
 
   Basel, 07 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today 
announced the launch of the Elecsys Anti-p53 immunoassay for the in 
vitro quantitative determination of anti-p53 antibodies. This test is 
used to aid physicians to diagnose throat cancer, bowel cancer and 
breast cancer in patients, in conjunction with other diagnostic tests. 
The assay is now available for all markets accepting the CE Mark. 
 
 
 
   "The addition of our Elecsys Anti-p53 immunoassay will help clinicians 
to quickly and reliably diagnose several prevalent cancers and might 
assist in leading to a better prognosis for many patients.", said Thomas 
Schinecker, CEO Roche Diagnostics. "Beyond breakthrough cancer medicines, 
Roche also offers a growing number of testing solutions to help 
physicians diagnose and treat people with cancer. 
 
 
 
   p53 is protein which, when active, helps to regulate processes which 
stop tumors from developing. A mutation of p53 is present in half of 
solid tumor cancers and is the most common genetic change identified so 
far in human cancers.(1) Certain mutations of p53 can lead to a build up 
of p53 which results in the formation of anti-p53 autoantibodies. 
Autoantibodies are antibodies that mistakenly target and react with a 
person's own tissues. Between 20-50% of patients with mutated p53 will 
produce anti-p53 autoantibodies.(2) This mutation causes the tumor 
suppressive function of p53 to switch to a tumor-promoting function and 
thus cancer development. 
 
 
 
   Early appearance of anti-p53 antibodies during tumour development may 
have potential to detect malignant changes.(3) The Elecsys Anti-p53 
immunoassay detects these anti-p53 antibodies and, when used with other 
diagnostic tests, can help to diagnose certain cancers, at an earlier 
stage, which may help to improve patient outcomes. Determining the 
presence of anti-p53 antibodies may also be useful for monitoring 
cancerous cells that are still in the body following treatment.(4) In 
addition, the Elecsys Anti-p53 test could aid in determining which 
patients may require less invasive treatment procedures, as part of 
their cancer treatment. 
 
 
 
   About Elecsys Anti-p53 
 
   Elecsys Anti-p53 immunoassay for the in vitro quantitative determination 
of anti-p53 autoantibodies in human serum and plasma. Elecsys Anti-p53 
is a high precision immunoassay, with a low turn-around time for testing, 
complementing our overall tumor marker portfolio.  The new Elecsys 
Anti-p53 immunoassay uses the well-established electrochemiluminescence 
immunoassay "ECLIA" technology and is intended for use on cobas e 
immunoassay analyzers. 
 
   For further information on Elecsys immunoassays visit 
https://www.globenewswire.com/Tracker?data=OFh5-DMScoDJWAWjTQjpGnkwWG40yJalCF2tjqceDfzrPlTpwBpooI-EsXD1O-j82u8l5HZQps5g2FVDgScTj6ncnImPX4wnlKP33UXbLYaGrOP3ngJ2uhv9XRht4QyC5fnUoQih3ySzuBC23gmCun9OestnI_CVytpBHGsfSnE= 
here. 
 
 
 
   About Roche 
 
   Roche is a global pioneer in pharmaceuticals and diagnostics focused on 
advancing science to improve people's lives. The combined strengths of 
pharmaceuticals and diagnostics under one roof have made Roche the 
leader in personalised healthcare -- a strategy that aims to fit the 
right treatment to each patient in the best way possible. 
 
 
 
   Roche is the world's largest biotech company, with truly differentiated 
medicines in oncology, immunology, infectious diseases, ophthalmology 
and diseases of the central nervous system. Roche is also the world 
leader in in vitro diagnostics and tissue-based cancer diagnostics, and 
a frontrunner in diabetes management. 
 
 
 
   Founded in 1896, Roche continues to search for better ways to prevent, 
diagnose and treat diseases and make a sustainable contribution to 
society. The company also aims to improve patient access to medical 
innovations by working with all relevant stakeholders. More than thirty 
medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
 
 
 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2020 employed more than 100,000 people worldwide. 
In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 
58.3 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit 
https://www.globenewswire.com/Tracker?data=QHKDODALEboRByZfyzte8LCy10_ZTCdqDMWEVxWMGygZBTcIba16mwDFruooSOJTePpwh7oOkCLxVMbU5dXbiQ== 
www.roche.com. 
 
 
 
   All trademarks used or mentioned in this release are protected by law. 
 
 
 
   References 
 
   [1] Yue X, et al. J Mol Biol 2017;429:1595-606 
 
   [2] Suppiach et al. World J Gastroenterol 2013 August 7; 19(29): 
4651-4670 
 
   [3] Soussi T. Cancer Res 2000;60:1777-88 
 
   [4] Kastenhuber E & Lowe S. Cell 2017;170(6):1062-78 
 
   Roche Group Media Relations 
 
   Phone: +41 61 688 8888 / e-mail: 
https://www.globenewswire.com/Tracker?data=TYPp-HYIALtAqdb8dmp6yImRSNrbsc-Ywh6k-dQHe0HUMcdYh2fLZjv_eU9KNKbsWgN5v6fwq5HcT2f2K4CYj3ggshn333fNqvo0a-yP3rs1GMFxFCf6TL_TKst06wWd 
media.relations@roche.com 
 
 
 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: +41 61 688 31 10     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
Dr. Barbara von Schnurbein 
 Phone: +41 61 687 89 67 
 
 
 
 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: +41 61 68-78503                        Phone: +41 61 68-83894 
 e-mail: mailto:karl.mahler@roche.com          e-mail: mailto:jon_kaspar.bayard@roche.com 
 karl.mahler@roche.com                         jon_kaspar.bayard@roche.com 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: +41 61 68-88027                        Phone: +41 61 68-75284 
 e-mail: mailto:sabine.borngraeber@roche.com   e-mail: mailto:bruno.eschli@roche.com 
 sabine.borngraeber@roche.com                  bruno.eschli@roche.com 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: +41 61 68-84814                        Phone: +41 61 68-72942 
 e-mail: mailto:birgit.masjost@roche.com       e-mail: mailto:gerard.tobin@roche.com 
 birgit.masjost@roche.com                      gerard.tobin@roche.com 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: +1 650 225 3217                        Phone: +1 650 467 8737 
 e-mail: mailto:kalm.loren@gene.com            e-mail: mailto:tuomi.lisa@gene.com 
 kalm.loren@gene.com                           tuomi.lisa@gene.com 
--------------------------------------------  ------------------------------------------- 
 
 
 
   Attachment 
 
 
   -- 07042021_MR_Elecsys Anti-p53_EN 
      https://ml-eu.globenewswire.com/Resource/Download/4e47c6a3-a0aa-41be-837c-cdf396611912 
 
 
 
 
 
 
 

(END) Dow Jones Newswires

April 07, 2021 01:00 ET (05:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. -2.21% 4250 End-of-day quote.-22.77%
PATIENT ACCESS SOLUTIONS, INC. -6.56% 0.0057 Delayed Quote.-69.50%
ROCHE HOLDING AG -1.10% 345.3 Delayed Quote.12.99%
All news about ROCHE HOLDING AG
12:25pInsulin pump Accessories Market Development, Outline, Competitive perspective..
AQ
06/18Ahead of pivotal AGM, Toshiba board chairman vows to be 'agent of positive ch..
RE
06/17ROCHE HOLDINGS AGá : Deutsche Bank reiterates its Neutral rating
MD
06/17Synlogic, Roche in Bowel-Disease Collaboration
DJ
06/17ROCHEá : Syncona CFO to Retire; Three New Executives Named
MT
06/17ROCHEá : Check You Employment Agreement's Restrictive Covenant
AQ
06/16WALL STREET STOCK EXCHANGE : How yesterday’s data could affect Fed policy
06/16Atea Pharma Hits Development Milestone for Covid-19 Treatment
DJ
06/16ROCHEá : Atea Pharmaceuticals Announces Achievement of AT-527 Development Milest..
AQ
06/16ROCHEá : Regeneron COVID-19 Antibody Cocktail Reduces Death Risk in Late-Stage T..
MT
More news
Financials
Sales 2021 60 597 M 65 938 M 65 938 M
Net income 2021 14 513 M 15 792 M 15 792 M
Net cash 2021 4 591 M 4 996 M 4 996 M
P/E ratio 2021 20,1x
Yield 2021 2,72%
Capitalization 299 B 325 B 325 B
EV / Sales 2021 4,86x
EV / Sales 2022 4,71x
Nbr of Employees 101 465
Free-Float 83,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 345,30 CHF
Average target price 355,40 CHF
Spread / Average Target 2,92%
EPS Revisions
Managers and Directors
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG12.99%328 650
JOHNSON & JOHNSON4.10%431 456
PFIZER, INC.7.09%220 661
NOVARTIS AG3.00%210 615
ABBVIE INC.7.07%202 639
ELI LILLY AND COMPANY29.44%202 413